JP2010522212A - 間充織幹細胞とその使用 - Google Patents

間充織幹細胞とその使用 Download PDF

Info

Publication number
JP2010522212A
JP2010522212A JP2009554770A JP2009554770A JP2010522212A JP 2010522212 A JP2010522212 A JP 2010522212A JP 2009554770 A JP2009554770 A JP 2009554770A JP 2009554770 A JP2009554770 A JP 2009554770A JP 2010522212 A JP2010522212 A JP 2010522212A
Authority
JP
Japan
Prior art keywords
animal
mesenchymal stem
stem cells
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522212A5 (https=
Inventor
アガーウォル，サディープタ
エフ． ピテンガー，マーク
バーニー，ティモシー
ダニルコビッチ，アラ
Original Assignee
オシリス セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オシリス セラピューティクス，インコーポレイティド filed Critical オシリス セラピューティクス，インコーポレイティド
Publication of JP2010522212A publication Critical patent/JP2010522212A/ja
Publication of JP2010522212A5 publication Critical patent/JP2010522212A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cardiology (AREA)
JP2009554770A 2007-03-22 2008-03-21 間充織幹細胞とその使用 Pending JP2010522212A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/726,676 US20080095749A1 (en) 2004-03-22 2007-03-22 Mesenchymal stem cells and uses therefor
PCT/US2008/057828 WO2008116157A2 (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014124452A Division JP5961220B2 (ja) 2007-03-22 2014-06-17 間充織幹細胞とその使用

Publications (2)

Publication Number Publication Date
JP2010522212A true JP2010522212A (ja) 2010-07-01
JP2010522212A5 JP2010522212A5 (https=) 2011-03-17

Family

ID=39735516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009554770A Pending JP2010522212A (ja) 2007-03-22 2008-03-21 間充織幹細胞とその使用
JP2014124452A Active JP5961220B2 (ja) 2007-03-22 2014-06-17 間充織幹細胞とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014124452A Active JP5961220B2 (ja) 2007-03-22 2014-06-17 間充織幹細胞とその使用

Country Status (10)

Country Link
US (3) US20080095749A1 (https=)
EP (6) EP2051718A2 (https=)
JP (2) JP2010522212A (https=)
KR (7) KR102519603B1 (https=)
CN (1) CN101626772A (https=)
BR (1) BRPI0802241A2 (https=)
CA (2) CA2637157C (https=)
DK (1) DK2123747T3 (https=)
ES (3) ES2891574T3 (https=)
WO (1) WO2008116157A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502579A (ja) * 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2022524764A (ja) * 2019-03-12 2022-05-10 ベーリンガー インゲルハイム ヴェテリナリー メディスン ベルギー 免疫調節性間葉系幹細胞
JP2023534524A (ja) * 2020-07-20 2023-08-09 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20050233443A1 (en) * 2004-03-30 2005-10-20 Toby Freyman Restenosis therapy using mesenchymal stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
NZ612888A (en) 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US20110177015A1 (en) * 2008-10-05 2011-07-21 Hymie Friedlander Skin and hair care using extract from conditioned medium cultured by mesenchymal stem cells and other regenerative cells
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
SG178064A1 (en) * 2009-07-21 2012-03-29 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
WO2011070974A1 (ja) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
EP2512516B1 (en) * 2009-12-18 2016-02-17 The Governing Council Of The University Of Toronto Injectable polymer composition for use as a cell delivery vehicle
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
KR101677293B1 (ko) * 2010-04-16 2016-11-17 서울대학교병원 줄기세포의 활성을 증가시키는 방법 및 상기 방법에 의해 제조된 고활성 줄기 세포
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
US20120087933A1 (en) * 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
CN101991880A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga/tcp和msc组成的制剂及其应用
CN101991878A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga和msc组成的制剂及其应用
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
CA2829586C (en) * 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
US8961956B2 (en) * 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
KR102246369B1 (ko) * 2011-11-30 2021-04-29 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
CN103191154B (zh) * 2012-01-06 2015-09-09 上海交通大学医学院 充质干细胞及其提取方法在制备银屑病的药物中的应用
EP2849765A4 (en) * 2012-05-16 2015-12-02 Univ Johns Hopkins STEM CELLS AS INDIVIDUALIZED MATERNAL THERAPY FOR THE PREVENTION OF EARLY BIRTHS
US9745551B2 (en) 2012-07-12 2017-08-29 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN115919901A (zh) * 2012-12-12 2023-04-07 麦瑟布莱斯特公司 治疗或预防呼吸病症的方法
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
WO2014100857A1 (en) * 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP2970914B1 (en) * 2013-03-13 2019-07-03 The University of Queensland A method of isolating cells for therapy and prophylaxis
JP6666240B2 (ja) 2013-04-12 2020-03-13 フランチェスカ， サベリオ ラ 移植のための臓器の改良
WO2014207679A1 (en) * 2013-06-25 2014-12-31 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
EP3052943B1 (en) * 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
JP6210049B2 (ja) 2014-11-04 2017-10-11 トヨタ自動車株式会社 車両
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
EP3286562B1 (en) * 2015-04-24 2020-08-12 TiGenix, S.A.U. Biomarkers for determining the clinical response to cell therapy
JP6824994B2 (ja) 2015-10-07 2021-02-03 サングイ バイオ ピーティーワイ． エルティーディー 血液の調製及びプロファイリング
CA3009369A1 (en) * 2015-12-22 2017-06-29 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN105769911A (zh) * 2016-03-23 2016-07-20 中国人民解放军第二军医大学 间充质干细胞诱导斑秃处毛发再生的方法及应用
KR101970642B1 (ko) * 2016-04-06 2019-05-17 주식회사 제이제이메이딘 줄기세포 배양용 배지조성물 및 그를 이용한 줄기세포 배양방법
EP3450548A4 (en) * 2016-04-27 2019-11-20 Rohto Pharmaceutical Co., Ltd. MESCHYMAL STEM CELL FOR EXPRESSING AT LEAST ONE CELL SURFACE MARKER SELECTED FROM THE GROUP OF CD201, CD46, CD56, CD147 AND CD165, AND METHOD FOR THE MANUFACTURE THEREOF AND PHARMACEUTICAL COMPOSITION WITH THE MESENCHYMAL STEM CELL AND METHOD FOR THE PRODUCTION THEREOF
EP3494977A4 (en) 2016-08-05 2020-03-18 Exostemtech Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF LUNG FIBROSE WITH FAT TISSUE EXOSOM OBTAINED FROM STEM CELLS AS AN ACTIVE SUBSTANCE
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN106492194A (zh) * 2016-11-30 2017-03-15 广州赛莱拉干细胞科技股份有限公司 一种干细胞外泌体制剂及其制备方法和应用
AU2017379367B2 (en) 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
CN110139657A (zh) * 2017-02-15 2019-08-16 日本乐敦制药株式会社 肺纤维化治疗剂、ptprr表达促进剂及肺纤维化治疗用试剂盒
EP3595683A1 (en) 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
CN119033819A (zh) 2017-11-22 2024-11-29 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN112566644A (zh) * 2018-07-17 2021-03-26 北京三有利和泽生物科技有限公司 牙源干细胞及其用途
JP7638529B2 (ja) * 2019-03-21 2025-03-04 アンテロジェン シーオー．，エルティーディー． 間葉系幹細胞－ヒドロゲルを含有する注射用組成物、並びにその製造、凍結及び解凍方法
WO2020251020A1 (ja) 2019-06-14 2020-12-17 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
CN110772537A (zh) * 2019-11-07 2020-02-11 深圳科康干细胞技术有限公司 脐带血间充质干细胞组合物在治疗慢性阻塞性肺疾病中的应用
BR112022017557A2 (pt) * 2020-03-05 2022-12-27 Mesoblast Int Sarl Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
CA3173216A1 (en) * 2020-04-03 2021-10-07 Silviu Itescu Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20210315937A1 (en) * 2020-04-08 2021-10-14 University Of South Florida Methods of treating inflammation
EP4146787A4 (en) 2020-05-08 2024-06-26 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111568930A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节nk细胞数量的应用
CN112076217A (zh) * 2020-10-26 2020-12-15 重庆医科大学附属第一医院 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法
IL302833A (en) 2020-11-13 2023-07-01 Advanced Therapeutic Lab Inc Medicinal compositions and methods using SVF derived from adipose tissue
AU2023323861A1 (en) * 2022-08-11 2025-02-27 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
CN117398450B (zh) * 2023-10-31 2025-03-11 北京三有利和泽生物科技有限公司 过表达肝细胞生长因子的间充质干细胞在制备哮喘药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521493A (ja) * 1998-07-31 2002-07-16 ジェンザイム コーポレーション 間葉幹細胞移植による心機能の改善
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2006112365A1 (ja) * 2005-04-14 2006-10-26 Japan Health Sciences Foundation 間葉系幹細胞を用いる肺気腫の治療

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843425A (en) * 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
CA2109729A1 (en) * 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
AU755888B2 (en) * 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
AU2999199A (en) * 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6835377B2 (en) * 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
US6878371B2 (en) * 2000-07-26 2005-04-12 Boston Scientific Scimed, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
KR20040081749A (ko) * 2002-01-14 2004-09-22 헨리 포드 헬쓰 시스템 혈관을 형성하고 혈관신생 및 영양 인자를 생성시키는데사용하기 위한 골수 기질 세포로부터의 물질
US6974991B2 (en) * 2003-10-29 2005-12-13 International Business Machines Corp. DRAM cell with buried collar and self-aligned buried strap
JP4326462B2 (ja) * 2004-11-19 2009-09-09 富士通株式会社 半導体集積回路の設計を支援する設計支援装置、設計支援プログラム、及び設計支援方法
TWM290409U (en) * 2005-10-14 2006-05-11 Ming Shiau Retractable barbeque rack
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
WO2007124594A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
CA2674028C (en) 2008-07-25 2012-09-04 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Recombinant b. pseudomallei adhesin protein and methods and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521493A (ja) * 1998-07-31 2002-07-16 ジェンザイム コーポレーション 間葉幹細胞移植による心機能の改善
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2006112365A1 (ja) * 2005-04-14 2006-10-26 Japan Health Sciences Foundation 間葉系幹細胞を用いる肺気腫の治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5010004468; ＴＡＮＧ　Ｙ　Ｌ: ＲＥＧＵＬＡＴＯＲＹ　ＰＥＰＴＩＤＥＳ Ｖ１１７　Ｎ１, 20040115, Ｐ３-１０, ＥＬＳＥＶＩＥＲ　ＳＣＩＥＮＣＥ　ＢＶ． *
JPN6012055952; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ Ｖｏｌ．１００, 2003, ｐ．８４０７-８４１１ *
JPN6012055953; Ａｍ．Ｊ．Ｒｅｓｐｉｒ．Ｃｅｌｌ　Ｍｏｌ．Ｂｉｏｌ． Ｖｏｌ．３３, 2005, ｐ．１４５-１５２ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502579A (ja) * 2015-01-08 2018-02-01 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2021046416A (ja) * 2015-01-08 2021-03-25 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー α１−アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2023002657A (ja) * 2015-01-08 2023-01-10 ジュンクツセル バイオメド マニュファクチャリング ゲーエムベーハー α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP7374527B2 (ja) 2015-01-08 2023-11-07 ジュンクツセル バイオメド マニュファクチャリング ゲーエムベーハー α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2024010006A (ja) * 2015-01-08 2024-01-23 ジュンクツセル バイオメド マニュファクチャリング ゲーエムベーハー α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
JP2022524764A (ja) * 2019-03-12 2022-05-10 ベーリンガー インゲルハイム ヴェテリナリー メディスン ベルギー 免疫調節性間葉系幹細胞
JP7572367B2 (ja) 2019-03-12 2024-10-23 ベーリンガー インゲルハイム ヴェテリナリー メディスン ベルギー 免疫調節性間葉系幹細胞
JP2023534524A (ja) * 2020-07-20 2023-08-09 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物
JP7691488B2 (ja) 2020-07-20 2025-06-11 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物

Also Published As

Publication number Publication date
EP3973970A1 (en) 2022-03-30
KR102357942B1 (ko) 2022-02-03
WO2008116157A3 (en) 2009-03-19
JP2014224117A (ja) 2014-12-04
KR102519603B1 (ko) 2023-04-10
WO2008116157A2 (en) 2008-09-25
EP3653217B1 (en) 2021-09-08
EP3653217A1 (en) 2020-05-20
ES2891574T3 (es) 2022-01-28
BRPI0802241A2 (pt) 2011-08-30
KR20220018084A (ko) 2022-02-14
KR20240008404A (ko) 2024-01-18
EP3973970B1 (en) 2024-08-28
CN101626772A (zh) 2010-01-13
KR20190031346A (ko) 2019-03-25
CA2637157A1 (en) 2008-09-21
KR20160027230A (ko) 2016-03-09
KR20250052468A (ko) 2025-04-18
EP2123747A1 (en) 2009-11-25
EP3095450B1 (en) 2019-10-23
KR20220166876A (ko) 2022-12-19
EP2051718A2 (en) 2009-04-29
CA2637157C (en) 2021-11-23
HK1136601A1 (en) 2010-07-02
KR20090122415A (ko) 2009-11-30
EP4438721A2 (en) 2024-10-02
JP5961220B2 (ja) 2016-08-02
EP3095450A1 (en) 2016-11-23
CA3134185A1 (en) 2008-09-21
EP2123747B1 (en) 2016-06-08
ES2988291T3 (es) 2024-11-20
DK2123747T3 (en) 2016-07-04
US20100330048A1 (en) 2010-12-30
EP4438721A3 (en) 2025-04-02
US20090220464A1 (en) 2009-09-03
US20080095749A1 (en) 2008-04-24
ES2765650T3 (es) 2020-06-10

Similar Documents

Publication Publication Date Title
JP5961220B2 (ja) 間充織幹細胞とその使用
US9694035B2 (en) Mesenchymal stem cells and uses therefor
JP7546239B2 (ja) 間葉幹細胞及びその使用法
JP2014139214A (ja) 間葉系幹細胞とその用途
HK40114915A (en) Mesenchymal stem cells and uses therefor
HK40069670A (en) Mesenchymal stem cells for use in treating idiopathic pulmonary fibrosis
HK1229734A1 (en) Mesenchymal stem cells for use in improving pulmonary function
HK40025518A (en) Mesenchymal stem cells for use in improving pulmonary function
HK40025518B (en) Mesenchymal stem cells for use in improving pulmonary function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140314

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140828